<DOC>
	<DOCNO>NCT01094405</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( clinical benefit rate ) MVA EBNA1/LMP2 vaccine patient persistent , recurrent metastatic nasopharyngeal carcinoma , impact disease progression .</brief_summary>
	<brief_title>Efficacy Recombinant Epstein-Barr Virus ( EBV ) Vaccine Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm diagnosis nasopharyngeal carcinoma ( NPC ) ( either initial diagnosis recurrence ) . NPC associate EBV infection , determine : NPC occur association raise serum titre IgA EBV viral capsid antigen ( VCA ) patient live area high incidence EBV+ undifferentiated NPC , The presence EBV confirm tumour immunohistochemistry EBV antigens situ hybridization EBV early RNA ( EBER ) , NPC persistent recurrent disease occur context elevate circulate EBV genome level Patients persistent , recurrent metastatic NPC residual EBV DNA follow completion conventional therapy ( chemotherapy radiotherapy ) . Patients residual mass site ( ) previous disease progress standard therapy currently appropriate . Patients residual recurrent disease low volume , cause minimal symptom standard therapy currently appropriate . Disease must amenable potentially curative radiotherapy surgery . Completion standard therapy malignancy least 4 week trial entry . Written inform consent ability patient cooperate treatment follow must ensure document . Age great 18 year . World Health Organisation ( WHO ) performance status 0 1 Life expectancy least 4 month . Female patient childbearing potential eligible , provide negative pregnancy test prior enrolment agree use appropriate medically approve contraception study six month last vaccination . Male patient must agree use appropriate medically approve contraception study six month last vaccination . Chemotherapy , radiotherapy , major surgery receive within 4 week trial entry . Known chronic active infection Hepatitis B , Hepatitis C Human Immunodeficiency Virus ( HIV ) . Current active autoimmune disease . Current active skin disease require therapy ( psoriasis , eczema etc ) . Ongoing active infection . History anaphylaxis severe allergy vaccination . Allergy egg egg product . Previous myeloablative therapy follow autologous allogeneic haematopoietic stem cell transplant . Patients splenectomy splenic irradiation , know splenic dysfunction . Receiving current immunosuppressive medication , include corticosteroid ( inhaled steroid acceptable ) . Pregnant lactating woman . Ongoing toxic manifestation previous treatment . Exceptions alopecia certain Grade 1 toxicity opinion Investigator exclude patient . Patients condition Investigator 's opinion would make patient good candidate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NPC persistent , recurrent metastatic disease patient</keyword>
</DOC>